A randomized recruitment intervention trial in Parkinson's disease to increase participant diversity: early stopping for lack of efficacy

被引:29
作者
Tilley, Barbara C. [1 ]
Mainous, Arch G., III [2 ]
Elm, Jordan J. [3 ]
Pickelsimer, Elisabeth [3 ]
Soderstrom, Lea H. [3 ]
Ford, Marvella E. [3 ,4 ]
Diaz, Vanessa A. [2 ]
Siminoff, Laura A. [5 ]
Burau, Keith [1 ]
Smith, Daniel W. [6 ]
机构
[1] Univ Texas Sch Publ Hlth, Div Biostat, Houston, TX 77030 USA
[2] Med Univ S Carolina, Dept Family Med, Charleston, SC 29425 USA
[3] Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC 29425 USA
[4] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA
[5] Virginia Commonwealth Univ, Sch Med, Dept Social & Behav Hlth, Richmond, VA USA
[6] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA
关键词
CANCER CLINICAL-TRIALS; DECISION-MAKING; PERCEPTIONS; COMMUNICATION; EXPERIENCE; BARRIERS; PHASE;
D O I
10.1177/1740774512436881
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Failure to include participants of diverse race and ethnicity (i.e. those other than European Caucasian, non-Hispanic) in clinical trials impedes the safe development of new therapies given the potential for racial/ethnicity-related variations in treatment response. Increasing diversity is problematic for low prevalence diseases, where most community-based approaches do not reach those with the disease. Purpose Increase racial/ethnic diversity of participants in a Parkinson's disease therapeutic trial. Methods We incorporated a randomized Ancillary Trial into the multisite National Institute of Neurologic Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study 1. Movement disorders clinics already participating in long-term trial 1 were eligible and were the unit of randomization and analysis. At least 14% of adult residents over age 55 and living within 30 miles of the eligible site were from a diverse population, or there was a near-by zip code with a highly diverse population. Eligible sites also agreed to be randomized. The intervention was designed to increase community physicians' trust in long-term trial 1 investigators and address recruitment barriers in diverse populations. Primary outcomes included percentage of participants from diverse racial/ethnic groups enrolled in long-term trial 1, and qualitative findings from key informant interviews of the Ancillary Trial investigators and coordinators at the end of the trial. Results The Ancillary Trial stopped early for lack of efficacy, conditional power less than 1%. The 17 intervention sites had 12.6% diverse participants compared to 15.6% in 15 control clinics; odds ratio 0.82 (95% confidence interval = 0.32-2.16). In key informant interviews, high enrollers of diverse participants reported more use of existing physician relationships, untargeted community outreach, and extensive efforts to overcome participants' barriers. Low enrollers reported more use of patients in their practices and placed more responsibility for low enrollment on prospective participants.
引用
收藏
页码:188 / 197
页数:10
相关论文
共 27 条
[1]   Influence of clinical communication on patients' decision making on participation in clinical trials [J].
Albrecht, Terrance L. ;
Eggly, Susan S. ;
Gleason, Marci E. J. ;
Harper, Felicity W. K. ;
Foster, Tanina S. ;
Peterson, Amy M. ;
Orom, Heather ;
Penner, Louis A. ;
Ruckdeschel, John C. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) :2666-2673
[2]   Crossroads in clinical trials [J].
Lisa J. Bain .
NeuroRX, 2005, 2 (3) :525-528
[3]   A review and assessment of potential sources of ethnic differences in drug responsiveness [J].
Bjornsson, TD ;
Wagner, JA ;
Donahue, SR ;
Harper, D ;
Karim, A ;
Khouri, MS ;
Murphy, WR ;
Roman, K ;
Schneck, D ;
Sonnichsen, DS ;
Stalker, DJ ;
Wise, SD ;
Dombey, S ;
Loew, C .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (09) :943-967
[4]  
Blustein J, 1998, J HEALTH CARE POOR U, V9, P153
[5]  
Curry L., 2003, The science of inclusion, recruiting and retaining racial and ethnic elders in health research, P1
[6]   PERCEPTIONS OF CANCER-PATIENTS AND THEIR PHYSICIANS INVOLVED IN PHASE-I TRIALS [J].
DAUGHERTY, C ;
RATAIN, MJ ;
GROCHOWSKI, E ;
STOCKING, C ;
KODISH, E ;
MICK, R ;
SIEGLER, M .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) :1062-1072
[7]   Epidemiology of Parkinson's disease [J].
de Lau, Lonneke M. L. ;
Breteler, Monique M. B. .
LANCET NEUROLOGY, 2006, 5 (06) :525-535
[8]   Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic review [J].
Ford, Jean G. ;
Howerton, Mollie W. ;
Lai, Gabriel Y. ;
Gary, Tiffany L. ;
Mid, Shari Bolen ;
Gibbons, M. Chris ;
Tilburt, Jon ;
Baffi, Charles ;
Tanpitukpongse, Teerath Peter ;
Wilson, Renee F. ;
Powe, Neil R. ;
Bass, Eric B. .
CANCER, 2008, 112 (02) :228-242
[9]   Continuing education meetings and workshops: effects on professional practice and health care outcomes [J].
Forsetlund, Louise ;
Bjorndal, Arild ;
Rashidian, Arash ;
Jamtvedt, Gro ;
O'Brien, Mary Ann ;
Wolf, Fredric ;
Davis, Dave ;
Odgaard-Jensen, Jan ;
Oxman, Andrew D. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (02)
[10]   Interventions to improve outpatient referrals from primary care to secondary care [J].
Grimshaw, JM ;
Winkens, RAG ;
Shirran, L ;
Cunningham, C ;
Mayhew, A ;
Thomas, R ;
Fraser, C .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (03)